ICON Public Limited Company
Health
Performance
7.7
Risk
Sell
Buy
Curious about the Scores? Learn more.

ICON Public Limited Company stock rating and score history

All changes in ratings, performance and outlook tracked over time.

10.07.2026
Slight bounce. Could be noise – or a comeback brewing.
25.06.2026
Off life support. Still risky, but slightly less scary.
16.06.2026
Barely upright. Still chaotic, but slowly finding some balance.
20.08.2025
Health’s picking up. Numbers look cleaner, cash flow tighter.
ICLR
ICON Public Limited Company
164.59
-0.96%
7.7
Sell
Buy
ICON Public Limited Company

ICON Public Limited Company stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does ICON Public Limited Company do? Business model and key facts

Get the full picture of ICON Public Limited Company: what it builds, where it operates, and how it makes money.

ICON Public Limited Company Profile

Sector: Healthcare

Industry: Medical - Diagnostics & Research

Employees (FY): 40100

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

shop
Company facts
Barry Balfe
CEO
40100
Employees worldwide
shop
Performance
19.01%
Last 12 months
-23.02%
Last 5 years
shop
Growth
$8.25B
Revenue year
$229.34M
Net income
shop
Valuation
$13.02B
Market Cap
62.40
Price/Earnings Ratio

Stocks related to ICON Public Limited Company

Selected based on industry alignment and relative market positioning.

MEDP
Medpace Holdings, Inc.
532.93
+0.95%
5.6
Sell
Buy
Medpace Holdings, Inc.
EXAS
Exact Sciences Corporation
104.91
+0.00%
5.9
Sell
Buy
Exact Sciences Corporation
GH
Guardant Health, Inc.
152.17
+2.77%
8.2
Sell
Buy
Guardant Health, Inc.
RVTY
Revvity, Inc.
109.79
+3.15%
4.5
Sell
Buy
Revvity, Inc.
CRL
Charles River Laboratories International, Inc.
217.81
-0.86%
5.6
Sell
Buy
Charles River Laboratories International, Inc.

Events and news impacting ICON Public Limited Company stock

Earnings, coporate decisions and industry developments that can affect the share price.

ICON Public Limited Company fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.